Huvitz Q1 2026 Net Income Up 45%, Announces 30% Dividend Payout Policy and Treasury Share Cancellation

Shareholder return: Target cash dividend ≥30% of consolidated net income (2025-2027); plan to cancel 234,104 treasury shares in H1 2026.
Consolidated: Revenue KRW 29.7bn (flat YoY), operating profit KRW 2.6bn (down 20% YoY), net income attributable to parent KRW 3.8bn (up 45% YoY) due to non-operating gains (FX, valuation).
Business: R&D 17.8% of revenue; key products: ophthalmic diagnostic (34%), lens edger (29%); dental subsidiary Ossvis improving; new US entity.
Risks: Net debt/equity 60.6%, 79% floating-rate borrowings, high FX exposure.